DAX23.239 +0,6%Est505.529 +0,3%MSCI World4.343 -0,1%Top 10 Crypto12,45 +6,2%Nas22.872 +2,7%Bitcoin77.085 +2,2%Euro1,1524 +0,1%Öl63,38 +1,4%Gold4.137 +1,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 Novo Nordisk A3EU6F RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Lufthansa 823212 Alphabet A (ex Google) A14Y6F Deutsche Telekom 555750 HENSOLDT HAG000 TKMS thyssenkrupp Marine Systems TKMS00 Amazon 906866 BASF BASF11 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich höher -- US-Aktien in Grün -- Novo Nordisk scheitert bei Alzheimer-Studie -- Telekom, Alphabet, TKMS, D-Wave, Siemens Energy, Rheinmetall & Co., DHL, Bayer, Lufthansa, NEL im Fokus
Top News
Ausblick: Alibaba-Aktie präsentiert Bilanzzahlen zum jüngsten Jahresviertel Ausblick: Alibaba-Aktie präsentiert Bilanzzahlen zum jüngsten Jahresviertel
Hype um NVIDIA-Aktie: UBS sieht KI-Rally noch lange nicht vor dem Ende Hype um NVIDIA-Aktie: UBS sieht KI-Rally noch lange nicht vor dem Ende
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Regeneron Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
662,80 EUR +6,20 EUR +0,94 %
BMN
761,42 USD +5,88 USD +0,78 %
BTT
Regeneron Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.68,98 Mrd. EUR

KGV18,58Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN881535

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75886F1075

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolREGN

Regeneron Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireLevi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
BenzingaPrice Over Earnings Overview: Regeneron Pharmaceuticals
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
BenzingaHere's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN
BenzingaHere's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
PR NewswireMarch 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
MotleyFoolWhy Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
ZacksImplied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options
BenzingaBeyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock
PR NewswireREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireContact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
PR NewswireAmerica's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
PR NewswireREGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
PR NewswireREGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
PR NewswireLevi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
PR NewswireREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireRegeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
PR NewswireShareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
PR NewswireREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BenzingaForecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
PR NewswireRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
BusinesswireDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
BenzingaWhat Analysts Are Saying About Regeneron Pharmaceuticals Stock
BenzingaWhat 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
BenzingaRegeneron Pharmaceuticals Unusual Options Activity
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireKuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
PR NewswireHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals News: auf dieser Seite finden Sie alle Regeneron Pharmaceuticals News und Nachrichten zur Regeneron Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regeneron Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regeneron Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.